GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Routine Lipid Management

Company
Amgen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Active, not recruiting NCT NCT05284747

    EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

    Not yet reported Amgen 6019 participants Est. completion 2027-05-29 120 sites Stand-alone
    Cardiovascular disease Other conditions: Coronary Revascularization
    View official trial listing →
  • Completed NCT NCT05434949

    Pre-analytical Influences on a Blood Test Study

    The Royal Wolverhampton Hospitals NHS Trust 25 participants Est. completion 2024-11-15 1 site
    Other conditions: IBS - Irritable Bowel Syndrome
    View official trial listing →
  • Not yet recruiting NCT NCT07803679

    A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

    Not yet reported Amgen 308 participants Est. completion 2029-04-30 Stand-alone
    Cardiovascular disease Other conditions: Hypercholesterolemia, Atheroma, Atherosclerotic Plaque
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.